Patients under steroid or immunosuppressive agents
Conditions
Interventions
Immunization of live attenuated vaccine
Sponsors
Nephrology and Rheumatology, National Center for Child Health and Development
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Equal or more than one years old. 2. Patients under treatment of one or more of steroid (PSL, mPSL) or immunosuppressants (Tac, CsA, MZR, AZP, MMF, EVR, MTX, 6-MP, sirolimus) 3. Negative or borderline antibody titer of one or more of the following viruses: measles, rubella, varicella, or mumps. 4. Immunological parameters are as follows 1) CD4 counts>500/mm3 2) PHA lymphocyte stimulatory test-stimulation index>101.6 3) Serum IgG level>300mg/dl 5. Patients who had the history of rituximab treatment should show CD+B cells of more than 1%. 6. Steroid treatment has to be under 1mg/kg/d or 2mg/kg/2d of PSL 7. Inactive primary disease.
Exclusion criteria
Exclusion criteria: 1) Patients under biological agents. 2) Patients under active primary disease. 3) Patients who are considered inappropriate for immunization of live attenuated vaccines according to the attached documents. 4) Patients who do not agree the study entry. 5) Patients who are considered inappropriate for immunization according to the physician in charge.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Analysis of seropositivity rates of measles, rubella, varicella and mumps after vaccination of MR vaccine, measles vaccine, rubella vaccine, varicella vaccine and mumps vaccine. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Comparison of antibodies between before and after vaccination of each virus. 2) Analysis of risk factors of vaccine failure. 3) Adverse events 4) Immunological analysis of cases who suffered from vaccine-strain infection after vaccination. | — |
Countries
Japan
Contacts
Public ContactKoichi Kamei
National Center for Child Health and Development Nephrology and Rheumatology
Outcome results
None listed